Anti-B4 Blocked Ricin Post Chemotherapy in Patients with Chronic Lymphocytic Leukemia--Long-term Follow-up of a Monoclonal Antibody-based Approach to Residual Disease

References

• Nadler, L.M., Anderson, K.C., Marti, G., et al. (1983) "B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes", Journal of Immunology 131, 244–250.
   PubMed Web of Science ®Google Scholar
• Lambert, J.M., Goldmacher, VS., Collison, A.R., Nadler, L.M. and Blatter, WA. (1991) "An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use", Cancer Research 51, 6236–6242.
   PubMed Web of Science ®Google Scholar
• Tedder, T.F. and Isaacs, CM. (1989) "Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily", Journal of Immunology 143, 712–717.
   PubMed Web of Science ®Google Scholar
• Goulet, AC., Goldmacher, VS., Lambert, J.M., et al. (1997) "Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization", Blood 90, 2364–2375.
   PubMed Web of Science ®Google Scholar
• Grossbard, ML., Freedman, AS., Ritz, J., et al. (1992) "Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion", Blood 79, 576–585.
   PubMed Web of Science ®Google Scholar
• Grossbard, ML., Multani, P.S., Freedman, AS., et al. (1999) "A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma", Clinical Cancer Research 5, 2392–2398.
   PubMed Web of Science ®Google Scholar
• Scadden, D.T., Schenkein, D.P., Bernstein, Z., et al. (1998) "Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma", Cancer 83, 2580–2587.
   PubMed Web of Science ®Google Scholar
• Longo, DL., Duffey, Pl., Gribben, J.G., et al. (2000) "Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study", Cancer Journal 6, 146–150.
   PubMed Web of Science ®Google Scholar
• el-Kareh, A.W., Braunstein, S.L. and Secomb, T.W. (1993) "Effect of cell arrangement and interstitial volume fraction on the diffusivity of monoclonal antibodies in tissue", Biophysical Journal 64, 1638–1646.
   PubMed Web of Science ®Google Scholar
• Jain, R.K. (1990) "Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors", Cancer Research 50, 814s–819s.
   Google Scholar
• Multani, P.S., O'Day, S., Nadler, L.M. and Grossbard, M.L. (1998) "Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma", Clinical Cancer Research 4, 2599–2604.
   Google Scholar
• Medeiros, L.J. and Carr, J. (1999) "Overview of the role of molecular methods in the diagnosis of malignant lymphomas", Archives of Pathology and Laboratory Medicine 123, 1189–1207.
   PubMed Web of Science ®Google Scholar
• Cheson, B.D., Bennett, J.M., Greyer, M., et al. (1996) "National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment", Blood 87, 4990–4997.
   PubMed Web of Science ®Google Scholar
• Kaplan, EL. and Meier, P. (1958) "Non-parametric estimation from incomplete observations", Journal of the American Statistical Association 53, 457–481.
   Web of Science ®Google Scholar
• CTEP Website http://ctep.info.nih.gov. The Revised Common Toxicity Criteria: Version 2.0.29] poj
   Google Scholar
• Rai, KR., Peterson, B.L., Appelbaum, ER., et al. (2000) "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia", New England Journal of Medicine 343, 1750–1757.
   PubMed Web of Science ®Google Scholar
• Johnson, S., Smith, A.G., Loftier, H., et al. (1996) "Multicentre prospective randomised trial of fludarabine versus cyclopho-sphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL", Lancet 347, 1432–1438.
   PubMed Web of Science ®Google Scholar
• Leporrier, M., Chevret, S., Cazin, B., et al. (2001) "Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients", Blood 98, 2319–2325.
   PubMed Web of Science ®Google Scholar
• Flinn, LW., Byrd, J.C., Morrison, C., et al. (2000) "Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies", Blood 96, 71–75.
   PubMed Web of Science ®Google Scholar
• O'Brien, S.M., Kantarjian, H.M., Cortes, J., et al. (2001) "Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia", Journal of Clinical Oncology 19, 1414–1420.
   PubMed Web of Science ®Google Scholar
• Cazin, B., Maloum, K., Divine, M., et al. (2001) "Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 59 patients", Blood 98, 772a.
   Web of Science ®Google Scholar
• Flinn, LW., Jemiai, Y., Bennett, J.M., et al. (2001) "Fludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia: ECOG 1997", Blood 98, 633a.
   Web of Science ®Google Scholar
• Byrd, J.C., Peterson, B.L., Morrison, V.A., et al. (2003) "Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)", Blood 101, 6–14.
   PubMed Web of Science ®Google Scholar
• Keating, M., Manshouri, T., O'Brien, S., et al. (2002) "A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination in chronic lymphocytic leukemia", Blood 100, 205a.
   Google Scholar
• Keating, M.J. (2001) "Progress in CLL, chemotherapy, antibodies and transplantation", Biomedicine and Phannacotherapy 55, 524–528.
   PubMed Web of Science ®Google Scholar
• O'Connor, R., Liu, C., Ferris, C.A., et al. (1995) "Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors", Blood 86, 4286–4294.
   PubMed Web of Science ®Google Scholar
• Liu, C., Lambert, J.M., Teicher, BA., Blattler, WA. and O'Connor, R. (1996) "Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and che-motherapeutic drugs", Blood 87, 3892–3898.
   PubMed Web of Science ®Google Scholar
• Grossbard, M.L., Lambert, J.M., Goldmacher, VS., et al. (1993) "Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms", Journal of Clinical Oncology 11, 726–737.
   PubMed Web of Science ®Google Scholar
• Grossbard, M.L., Gribben, J.G., Freedman, AS., et al. (1993) "Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma", Blood 81, 2263–2271.
   PubMed Web of Science ®Google Scholar
• Dinndorf, P., Krailo, M., Liu-Mares, W., et al. (2001) "Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma", Journal of Immunotherapy.
   Google Scholar